Equities analysts forecast that Radius Health Inc (NASDAQ:RDUS) will announce ($0.86) earnings per share for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Radius Health’s earnings, with the highest EPS estimate coming in at ($0.75) and the lowest estimate coming in at ($1.03). Radius Health reported earnings per share of ($0.99) in the same quarter last year, which would indicate a positive year-over-year growth rate of 13.1%. The business is scheduled to announce its next earnings results after the market closes on Wednesday, August 7th.
According to Zacks, analysts expect that Radius Health will report full-year earnings of ($3.58) per share for the current fiscal year, with EPS estimates ranging from ($4.29) to ($2.82). For the next fiscal year, analysts anticipate that the business will report earnings of ($2.79) per share, with EPS estimates ranging from ($4.08) to ($1.45). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that follow Radius Health.
Radius Health (NASDAQ:RDUS) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.01. Radius Health had a negative return on equity of 233.12% and a negative net margin of 176.84%. The business had revenue of $29.84 million for the quarter, compared to analyst estimates of $35.35 million. During the same period last year, the firm posted ($1.11) earnings per share. Radius Health’s revenue was up 105.1% compared to the same quarter last year.
Several brokerages recently issued reports on RDUS. Goldman Sachs Group raised Koninklijke KPN from a “neutral” rating to a “buy” rating in a research report on Wednesday, May 29th. BidaskClub lowered Weyco Group from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 13th. Citigroup set a $14.00 price objective on Coty and gave the company a “hold” rating in a research note on Thursday, May 30th. HC Wainwright upped their target price on Palatin Technologies from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. Finally, Zacks Investment Research cut GALP ENERGIA SG/ADR from a “hold” rating to a “sell” rating in a report on Monday, May 6th. Six equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Radius Health has a consensus rating of “Hold” and an average price target of $33.14.
Shares of RDUS traded down $1.18 during mid-day trading on Thursday, reaching $21.52. 414,809 shares of the company were exchanged, compared to its average volume of 547,920. The company has a market capitalization of $992.22 million, a PE ratio of -4.41 and a beta of 1.06. The stock has a 50 day simple moving average of $23.01. The company has a debt-to-equity ratio of 6.75, a current ratio of 5.16 and a quick ratio of 5.04. Radius Health has a 52 week low of $12.81 and a 52 week high of $26.40.
In other Radius Health news, Director Anthony Rosenberg sold 1,584 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $24.60, for a total transaction of $38,966.40. Following the sale, the director now directly owns 8,716 shares of the company’s stock, valued at $214,413.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Joseph Francis Kelly acquired 2,500 shares of Radius Health stock in a transaction on Friday, June 7th. The shares were bought at an average cost of $21.81 per share, for a total transaction of $54,525.00. Following the completion of the purchase, the vice president now directly owns 7,500 shares of the company’s stock, valued at $163,575. The disclosure for this purchase can be found here. 4.00% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. California Public Employees Retirement System increased its position in shares of Radius Health by 25.3% during the fourth quarter. California Public Employees Retirement System now owns 73,700 shares of the biopharmaceutical company’s stock worth $1,215,000 after purchasing an additional 14,900 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Radius Health by 8.6% during the 4th quarter. Geode Capital Management LLC now owns 457,063 shares of the biopharmaceutical company’s stock worth $7,536,000 after acquiring an additional 36,093 shares in the last quarter. Two Sigma Investments LP purchased a new stake in shares of Radius Health during the 4th quarter worth about $981,000. Paloma Partners Management Co purchased a new stake in shares of Radius Health during the 4th quarter worth about $218,000. Finally, Metropolitan Life Insurance Co. NY lifted its stake in Radius Health by 395.0% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 13,549 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 10,812 shares in the last quarter.
Radius Health Company Profile
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Recommended Story: What do I need to know about analyst ratings?
Get a free copy of the Zacks research report on Radius Health (RDUS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.